Ireland vs Turkmenistan: Treatment for hypertension, male
Ireland
37.6%
in 2019
Turkmenistan
38.2%
in 2019
Ireland rank
82nd
Turkmenistan rank
79th
Treatment for hypertension, male over time
- Ireland
- Turkmenistan
How they compare
Turkmenistan currently reports 38.2% against 37.6% in Ireland, a difference of 0.6%.
The two have swapped places 2 times across 30 shared years of data; in 1990 it was Turkmenistan ahead.
Ireland ranks 82nd and Turkmenistan ranks 79th of 192 countries.
Turkmenistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Ireland | Turkmenistan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 18.1% | 20.3% | 2.2% | Turkmenistan |
| 2000s | 27.8% | 28.4% | 0.6% | Turkmenistan |
| 2010s | 35.9% | 35.9% | 0.1% | Turkmenistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment for hypertension, male, Ireland or Turkmenistan?
- Turkmenistan, at 38.2% against 37.6% in Ireland as of 2019.
- What is the difference in treatment for hypertension, male between Ireland and Turkmenistan?
- 0.6%, with Turkmenistan ahead.
- How many years of comparable data are there for Ireland and Turkmenistan?
- 30 years are reported by both, from 1990 to 2019.
- How do Ireland and Turkmenistan rank globally for treatment for hypertension, male?
- Ireland ranks 82nd and Turkmenistan ranks 79th of 192 countries.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Treatment for hypertension, male (% of male adults ages 30-79 with hypertension). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Treatment for hypertension, male, is the percentage of adults ages 30-79 with hypertension who were taking medicine for hypertension. Hypertension is defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension.